Pamela Trillo Aliaga

Post-Progression Analysis of EGFR-Mutant NSCLC Following Osimertinib Therapy in Real-World Settings

Ilaria Attili, Carla Corvaja, Gianluca Spitaleri et al. · Cancers · 2024 · 17 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 < 50%

Ilaria Attili, Carmine Valenza, Celeste Santoro et al. · Frontiers in Oncology · 2022 · 14 citations · Full text

Medicine, Oncology, Pharmacology +17

Safety of COVID-19 mRNA Vaccines in Patients with Cancer Enrolled in Early-Phase Clinical Trials

Pamela Trillo Aliaga, Dario Trapani, José Luís Sandoval et al. · Cancers · 2021 · 12 citations · Full text

Medicine, Oncology, Pharmacology +16

Pegylated Liposomal Doxorubicin (Caelyx®) as Adjuvant Treatment in Early-Stage Luminal B-like Breast Cancer: A Feasibility Phase II Trial

Silvia Dellapasqua, Pamela Trillo Aliaga, Elisabetta Munzone et al. · Current Oncology · 2021 · 12 citations · Full text

Medicine, Oncology, Pharmacology +14

Evolution of biological features of invasive lobular breast cancer: Comparison between primary tumour and metastases

Pamela Trillo Aliaga, J.L.B.R.G. Sandoval, Dario Trapani et al. · European Journal of Cancer · 2023 · 12 citations

Medicine, Cancer Biology, Oncology +16